West Pharmaceutical Services, Inc.
General ticker "WST" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $20.2B (TTM average)
West Pharmaceutical Services, Inc. follows the US Stock Market performance with the rate: 55.8%.
Estimated limits based on current volatility of 1.1%: low 375.95$, high 384.30$
Factors to consider:
- Earnings expected soon, date: 2026-10-29 bmo
- Company included in S&P500 list
- Company pays dividends (irregularly): last record date 2026-07-29, amount 0.22$ (Y0.06%)
- Total employees count: 10800 (+1.9%) as of 2025
- US accounted for 43.3% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Geopolitical risks, Supply chain disruptions, Currency fluctuations, Cybersecurity threats, Customer concentration
- Current price 15.5% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [238.10$, 332.46$]
- 2026-12-31 to 2027-12-31 estimated range: [252.10$, 349.36$]
Financial Metrics affecting the WST estimates:
- Negative: with PPE of 37.8 at the end of fiscal year the price was high
- Positive: 15.80 < Operating profit margin, % of 19.35
- Positive: 2.37 < Operating cash flow per share per price, % of 3.78
- Positive: 7.19 < Return on assets ratio (scaled to [-100,100]) of 10.09
- Positive: -16.84 < Industry operating profit margin (median), % of -7.42
- Positive: 0.90 < Industry operating cash flow per share per price (median), % of 1.58
- Negative: 0 < Interest expense per share per price, % of 0
- Positive: -2.60 < Investing cash flow per share per price, % of -1.43
- Positive: 69.38 < Shareholder equity ratio, % of 74.38 <= 81.92
Short-term WST quotes
Long-term WST plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,918.40MM | $2,872.20MM | $3,022.90MM |
| Operating Expenses | $2,242.40MM | $2,302.30MM | $2,438.00MM |
| Operating Income | $676.00MM | $569.90MM | $584.90MM |
| Non-Operating Income | $22.00MM | $15.60MM | $16.00MM |
| Interest Expense | $9.00MM | $3.00MM | $0.50MM |
| R&D Expense | $68.40MM | $69.10MM | $74.30MM |
| Income(Loss) | $698.00MM | $585.50MM | $600.90MM |
| Taxes | $122.30MM | $107.50MM | $121.60MM |
| Other Income(Loss) | $17.70MM | $14.70MM | $14.40MM |
| Net Income(Loss)* | $593.40MM | $492.70MM | $493.70MM |
| Stockholders Equity | $2,881.00MM | $2,682.30MM | $3,176.00MM |
| Inventory | $434.70MM | $377.00MM | $443.90MM |
| Assets | $3,829.50MM | $3,643.40MM | $4,270.00MM |
| Operating Cash Flow | $776.50MM | $653.40MM | $754.80MM |
| Capital expenditure | $362.00MM | $377.00MM | $285.90MM |
| Investing Cash Flow | $-368.70MM | $-378.70MM | $-285.90MM |
| Financing Cash Flow | $-459.60MM | $-622.60MM | $-185.10MM |
| Earnings Per Share** | $7.99 | $6.75 | $6.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.